Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug-drug interactions via CYP3A metabolism and transporters

• Main Authors: Aline Barth (Author), Caroline R. Perry (Author), Shaila Shabbir (Author), Maciej J. Zamek‐Gliszczynski (Author), Sebin Thomas (Author), Etienne F. Dumont (Author), Darin B. Brimhall (Author), Dung Nguyen (Author), Meenakshi Srinivasan (Author), Brandon Swift (Author)
• Format: Book
• Published: Wiley, 2023-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Gepotidacin is a novel triazaacenaphthylene antibiotic in phase III development. Based on nonclinical in vitro characterization of gepotidacin metabolism, two phase I studies were conducted in healthy participants to investigate clinical drug-drug interactions (DDIs). We assessed gepotidaci...